Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferonγ (IFNγ) are recognised by T cells while resisting destruction by natural killer (NK) cells

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1408-1412

  Zier, K S ^a   Gansbacher, B ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene therapy; IFN; IL 2; T cells; Tumour vaccines

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR VACCINE;

ARTICLE; CANCER GROWTH; CELL MIGRATION; CYTOLYSIS; FIBROSARCOMA; FLOW CYTOMETRY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 0030059135     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00099-8     Document Type: Article

References (32)

1. Pardoll DM. Cancer vaccines. Immunol Today 1993, 14, 310-316.
2. Rosenthal F, Zier KS, Gansbacher B. Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity. Curr Opin Oncol, 1994, 6, 611-615.
3. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1993, 15, 48-51.
4. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the Interleukin-2 and Interferon γ cDNAs. Blood 1994, 83, 1289-1298.
5. Erard R, Corthesy M, Nabholz M, et al. Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J Immunol 1985, 134, 1644-1652.
6. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47, 187-376.
7. Wallach D, Fellous M, Revel M. Preferential effect of interferon-gamma on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982, 299, 833-836.
8. + T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992, 176, 1423-1431.
9. Ljunggren HC, Karre K. In search of the "missing self?" MHC molecules and NK cell recognition. Immunol Today 1990, 11, 237-244.
10. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswell P. NK susceptibility varies inversely with target cell class I HLA expression. J Immunol 1987, 138, 1657-1659.
11. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76, 287-299.
12. Englehard V. Structure of peptides associated with class I and class II MHC molecules. Ann Rev Immunol 1994, 12, 181-207.
13. Alosco TR, Croy BA, Gansbacher B, Wang HQ, Rao U, Bankaert R. Tumor cells secreting IL2 stimulate a local anti-tumor response independent of functional B or T lymphocytes. Cancer Immunol Immunother 1993, 36, 364-372.
14. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. IL-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990, 172, 1217-1224.
15. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res 1990, 50, 7820-7825.
16. Gillis S, Ferm M, Ou W, Smith K. T cell growth factor: parameters of production and quantitative microassay for activity. J Immunol 1978, 120, 2027-2032.
17. Springer TA. Adhesion molecules of the immune system. Nature 1990, 346, 425-434.
18. Cabrero JG, Freeman GJ, Lane WS, Reiser H. Identification, by protein sequencing and gene transfection, of sgp-60 as the murine homologue of CD48. Proc Natl Acad Sci USA 1993, 90, 3418-3422.
19. Linsley PS, Ledbetter JA. T cell co-stimulation and in vivo tolerance. Curr Opin Immunol 1993, 5, 747-752.
20. Jenkins MK, Johnson JG. Molecules involved in T cell costimulation. Curr Opin Immunol 1993, 5, 361-367.
21. Karlhofer FM, Hunziker R, Reichlin A, Margulies DN, Yokoyama WM. Host MHC class I molecules modulate in vivo expression of a natural killer cell receptor. J Immunol 1994, 153, 2407-2416.
22. Daniels BF, Karlhofer RM, Seaman WE, Yokoyama WM. A natural killer cell receptor specific for a major histocompatibility complex class I molecule. J Exp Med 1994, 180, 687-692.
23. Golumbek PT, Lazenby AJ, Levitzky HI, et al. Treatment of established renal cancer engineered to secrete interleukin-4. Science 1991, 254, 713-716.
24. Porgador A, Tzehoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992, 52, 3679-3686.
25. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993, 177, 1127-1134.
26. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90, 3539-3543.
27. Porgardor A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Anti-metastatic vaccination of tumor-bearing mice with two types of IFN-γ gene inserted tumor cells. J Immunol 1993, 150, 1458-1470.
28. Salvadori S, Gansbacher B, Pizzimenti A, Zier KS. T cells from mice vaccinated with IL-2-secreting tumor cells are protected from the onset of signal transduction abnormalities seen in T cells of mice bearing parental tumors. J Immunol 1994, 153, 5176-5182.
29. Salvadori S, Gansbacher B, Zier KS. Functional differences are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells. Cancer Gene Ther 1994, 1, 165-170.
30. Zier KS, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today 1996, 17, 39-45.
31. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by the IL-2 gene. J Immunol 1992, 149, 3627-3635.
32. Schmidt W, Schweighoffer T, Herbst E, et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995, 9, 4711-4714.